Teva Octreotide Acetate Injection Recall: Sterility Assurance Loss
Teva Pharmaceuticals is recalling Octreotide Acetate Injection 100 mcg/mL (Lot #31327466B, expiring 08/2021) nationwide due to lack of assurance of sterility. The affected product was distributed nationwide, including Puerto Rico.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: This is an FDA Class II recall. Loss of sterility assurance in an injectable drug represents a significant risk of serious health consequences, including infection, sepsis, and other potentially serious complications. Although no illnesses have been reported in the source text, the hazard itself—compromised sterility in an injectable product—creates substantial risk of harm.
Plain-English summary
Teva Pharmaceuticals USA is recalling Octreotide Acetate Injection 100 mcg/mL, 1 mL single-dose vials (NDC 0703-3311-01) because the company cannot assure the sterility of the product. The recall affects Lot #31327466B with an expiration date of 08/2021.
The product was distributed nationwide, including Puerto Rico. A total of 3,067 vials are being recalled. Octreotide Acetate is an injectable prescription medication, and sterility is critical for injectable products to prevent infections and other serious complications.
Patients currently using this medication should consult their healthcare provider immediately about their treatment options and whether they need to switch to an alternative supply. Healthcare providers and pharmacies should stop dispensing this lot and contact patients who may have received vials from this lot.
The recalled product
- Product
- Octreotide Acetate Injection 100 mcg/mL, 1 mL single-dose vial, Rx only, Teva Pharmaceuticals USA. Inc. North Wales, PA 19454, NDC 0703-3311-01
- Manufacturer
- Teva Pharmaceuticals USA
- Category
- Drug — Injectable Pharmaceutical
- Affected units
- 3,067
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 31327466B
- exp. date 08/2021
Distribution
Part of a larger recall action
This product is one of 19 recalled by Teva Pharmaceuticals USA under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 19 products in this recall →Related recalls
Same manufacturer · Teva Pharmaceuticals USA
See all →- ModerateDoxylamine Succinate and Pyridoxine Hydrochloride Tablets Recalled for Failed Dissolution
FDA (Drugs) · 2022-02-09
- LowPrescription Drug Recall: Mimvey Mislabeling by Teva Pharmaceuticals
FDA (Drugs) · 2022-02-09
- ModerateTretinoin Capsules 10 mg Recalled for Failed Dissolution Specifications
FDA (Drugs) · 2022-02-09
- LowMimvey Estradiol/Norethindrone Prescription Drug Mislabeling Recall
FDA (Drugs) · 2022-02-09
- ModerateBrinzolamide Ophthalmic Suspension recalled for defective container caps
FDA (Drugs) · 2022-01-26
Same hazard · sterility loss
See all →- SevereChloraPrep One-Step Topical Solution Sterility Assurance Recall
FDA (Drugs) · 2026-07-01
- SevereNicardipine Hydrochloride Injection Recalled for Potential Sterility Loss
FDA (Drugs) · 2025-05-07
- HighSterile surgical drapes recalled due to potential packaging breach
FDA (Devices) · 2025-03-26
- HighMedline Proxima Sterile Surgical Drapes Recalled for Packaging Breach Risk
FDA (Devices) · 2025-03-26
- HighMedline Proxima sterile surgical drapes recalled due to potential packaging breach
FDA (Devices) · 2025-03-26